Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction.

Tomic JL, Pensalfini A, Head E, Glabe CG.

Neurobiol Dis. 2009 Sep;35(3):352-8. doi: 10.1016/j.nbd.2009.05.024.

2.

A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain.

Sarsoza F, Saing T, Kayed R, Dahlin R, Dick M, Broadwater-Hollifield C, Mobley S, Lott I, Doran E, Gillen D, Anderson-Bergman C, Cribbs DH, Glabe C, Head E.

Acta Neuropathol. 2009 Oct;118(4):505-17. doi: 10.1007/s00401-009-0530-3.

3.

Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers.

Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG.

Mol Neurodegener. 2007 Sep 26;2:18.

4.

Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.

Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, Yang F, Chen PP, Glabe CG, Takacs A, Hoffman DR, Frautschy SA, Cole GM.

Neurobiol Dis. 2015 Oct;82:552-60. doi: 10.1016/j.nbd.2015.09.002.

5.

Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.

Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, Abramowski D, Kumar S, Yamaguchi H, Walter J, Fändrich M, Staufenbiel M, Thal DR.

Neurobiol Aging. 2012 Nov;33(11):2641-60. doi: 10.1016/j.neurobiolaging.2011.12.032.

PMID:
22305478
6.

[Involvement of beta-amyloid in the etiology of Alzheimer's disease].

Tomiyama T.

Brain Nerve. 2010 Jul;62(7):691-9. Review. Japanese.

PMID:
20675873
7.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072.

PMID:
21513747
8.

Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.

Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG.

J Neurochem. 2013 Aug;126(4):473-82. doi: 10.1111/jnc.12305.

9.

Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.

Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, Serrano-Pozo A, Frosch MP, Lowe V, Parisi JE, Petersen RC, Ikonomovic MD, López OL, Klunk W, Hyman BT, Gómez-Isla T.

Brain. 2013 Aug;136(Pt 8):2510-26. doi: 10.1093/brain/awt171.

10.

Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.

Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, Verbeek MM, Teunissen CE, Veerhuis R.

J Alzheimers Dis. 2015;45(1):35-43. doi: 10.3233/JAD-142136.

PMID:
25547634
11.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
12.

Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH.

Brain. 2013 May;136(Pt 5):1383-98. doi: 10.1093/brain/awt062.

13.

Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer's disease neuropathology.

Bjorklund NL, Reese LC, Sadagoparamanujam VM, Ghirardi V, Woltjer RL, Taglialatela G.

Mol Neurodegener. 2012 May 28;7:23. doi: 10.1186/1750-1326-7-23.

14.

Fibrillar seeds alleviate amyloid-β cytotoxicity by omitting formation of higher-molecular-weight oligomers.

Wu WH, Liu Q, Sun X, Yu JS, Zhao DS, Yu YP, Luo JJ, Hu J, Yu ZW, Zhao YF, Li YM.

Biochem Biophys Res Commun. 2013 Sep 27;439(3):321-6. doi: 10.1016/j.bbrc.2013.08.088.

PMID:
24012671
15.

Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease.

Takeda S, Hashimoto T, Roe AD, Hori Y, Spires-Jones TL, Hyman BT.

FASEB J. 2013 Aug;27(8):3239-48. doi: 10.1096/fj.13-229666.

16.

Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.

Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H.

J Alzheimers Dis. 2012;29(1):171-6. doi: 10.3233/JAD-2012-111361.

PMID:
22214781
17.

Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T.

BMC Neurosci. 2010 Oct 14;11:130. doi: 10.1186/1471-2202-11-130.

18.

Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity.

Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A.

Neurobiol Aging. 2012 Apr;33(4):825.e1-13. doi: 10.1016/j.neurobiolaging.2011.05.003.

PMID:
21683475
19.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2010 Jan;117(1):85-96. doi: 10.1007/s00702-009-0314-x.

20.

Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates.

Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE, Coe BC, Lablans A, Marques SA, Martinez AM, Klein WL, Houzel JC, Ferreira ST, Munoz DP, De Felice FG.

J Neurosci. 2014 Oct 8;34(41):13629-43. doi: 10.1523/JNEUROSCI.1353-14.2014.

Items per page

Supplemental Content

Support Center